Fluorescent Molecular Peroxidation Products: A Prognostic Biomarker of Early Neurologic Deterioration After Thrombolysis [Clinical Sciences]

Conclusions—
FMPPs might be a valuable biomarker of poor early neurological outcome and be related to the appearance of symptomatic intracranial hemorrhage in tissue plasminogen activator–treated patients, one of the most feared neurological complications after thrombolytic treatment of acute ischemic stroke.

Source: Stroke - January 27, 2014 Category: Neurology Authors: Llombart, V., Dominguez, C., Bustamante, A., Rodriguez-Sureda, V., Martin-Gallan, P., Vilches, A., Garcia-Berrocoso, T., Penalba, A., Hernandez-Guillamon, M., Rubiera, M., Ribo, M., Eschenfelder, C., Giralt, D., Molina, C. A., Alvarez-Sabin, J., Rosell, A Tags: Cerebrovascular disease/stroke, Acute Cerebral Infarction, Intracerebral Hemorrhage, Thrombolysis, Oxidant stress Clinical Sciences Source Type: research